afamelanotide (Scenesse)
Jump to navigation
Jump to search
Indications
- phototoxic reactions from erythropoietic protoporphyria
Dosage
Implant: 16 mg
Adverse effects
- implant site reaction
- nausea, oropharyngeal pain, cough
- fatigue, dizziness
- respiratory tract infection, somnolence
- melanocytic nevus, skin hyperpigmentation, non-acute porphyria
- skin irritation
More general terms
References
- ↑ RxNorm
- ↑ FDA Drug Approval, Oct 8, 2019 FDA approves first treatment to increase pain-free light exposure in patients with a rare disorder. https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-increase-pain-free-light-exposure-patients-rare-disorder